{
    "nctId": "NCT05184257",
    "briefTitle": "Zoladex\u00ae 10.8 BC RWS",
    "officialTitle": "The Effectiveness of Zoladex\u00ae 10.8 mg Compared to Zoladex\u00ae 3.6mg in the Treatment of Premenopausal and Perimenopausal Hormone Receptor Positive Breast Cancer: A Real-World Study",
    "overallStatus": "COMPLETED",
    "conditions": "Breast Cancer",
    "studyType": "OBSERVATIONAL",
    "phase": "N/A",
    "allocation": "N/A",
    "primaryPurpose": "N/A",
    "enrollmentCount": 1176,
    "primaryOutcomeMeasure": "Proportion of patients with serum E2 suppression at 12 weeks (\u00b14 weeks). Serum E2 suppression is defined as an E2 value below the upper limit of the menopausal reference range",
    "eligibilityCriteria": "Inclusion Criteria\n\n* Diagnosed with primary breast cancer\n* Female, \u226518 years old (at index date)\n* HR positive\n* Receive Zoladex\u00ae 10.8 mg or Zoladex\u00ae 3.6 mg treatment\n* Premenopausal status prior to the treatment of Zoladex\u00ae. Baseline premenopausal status will be confirmed if the patient's last E2 measurement within 180 days prior to the index date indicated premenopausal status or there was a recorded menstrual history within 180 days prior to the index date\n* At least one actual or expected E2 testing measurement within 8-28 weeks of the index date Exclusion Criteria\n* Patients received concurrent treatments that may affect E2 testing results",
    "sex": "FEMALE",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}